biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sniper007on Nov 14, 2013 6:03pm

271 Views

Post# 21907573

RE:RE:Bidding war?

Jdstox,
Thank you for your comments.
I thought any offer would need to be disclosed to shareholders, if the offer was indeed a serious one. I'm not sure what an informal offer would look like. Would it be company x asking BTI: "if we were to offer you x dollars per share, would you advise shareholders to take it?".
I suppose I fear that a company could make a lowball offer before we get a licensing deal, potentially picking it up for cheap, if uninformed/impatient shareholders agreed to the offering.
Again, it just surprises me that Roche and all other interested pharmas have not made a formal offering, especially with all the buying in the biotech sector.
Sniper

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario